-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
UKWyNE7oq8LoRUrZuWNdANIahPBr3IrX1eRX+ThRXzR7BK0Ir7NcyGLaoCUZ0U+Z
hLHjvgX+lGzyo0Pi0S9rjg==
UNITED STATES ý
QUARTERLY REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 or ¨
TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
to Commission file number 0-19041 AMERICAN
BIOGENETIC SCIENCES, INC. Registrant's
Telephone Number, Including Area Code: (212) 688-5688 Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes x No ¨ At September 30,
2008, the Registrant had 217,749,909 shares of common stock outstanding. Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act). Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act). Yes x No ¨ PART I - FINANCIAL
INFORMATION ITEM 1. ITEM 2. ITEM 4. PART II - OTHER
INFORMATION ITEM 1. ITEM 2. ITEM 3. ITEM 4. ITEM 5. PART I - FINANCIAL INFORMATION ITEM
1. FINANCIAL STATEMENTS Back
to Table of Contents The Registrant's unaudited interim financial statements
are attached hereto. Unaudited
Interim Financial Statements ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION Back to Table of Contents Some of the statements contained in this quarterly
report of American Biogenetic Sciences, Inc., a Delaware corporation discuss future
expectations, contain projections of our plan of operation or financial condition or state
other forward-looking information. Forward-looking statements give our current
expectations or forecasts of future events. You can identify these statements by the fact
that they do not relate strictly to historical or current facts. They use of words such as
"anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe," and other words and terms of
similar meaning in connection with any discussion of future operating or financial
performance. From time to time, we also may provide forward-looking statements in other
materials we release to the public. General Background American
Biogenetic Sciences, Inc., a Delaware corporation, is sometimes referred to herein as
"we", "us", "our", "Company" and the
"Registrant". The Registrant was formed in 1983 for the purpose of
researching, developing and marketing cardiovascular and neurobiology products for
commercial development and distributing vaccines. The Registrant's products were designed
for in vitro and in vivo diagnostic procedures and therapeutic drugs, and its products had
been identified for use in the treatment of epilepsy, migraine and mania,
neurodegenerative diseases, coronary artery diseases and cancer. The Registrant
commenced selling its products during the last quarter of 1997 but did not generate any
sufficient revenues from operations to fund its operating expenses. On September 19, 2002, the Registrant filed a petition
under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern District of
New York. On November 4, 2005, the Bankruptcy Court approved an order authorizing a change
in control and provided that the Company, subsequent to the bankruptcy proceeding, is free
and clear of all liens, claims and interests of others. Change in Control following Bankruptcy The Bankruptcy Court authorized Park Avenue
Group to appoint new members to the Registrant's board of directors and management, and
the authority to change the Registrant's articles of incorporation with respect to the
capital stock of the Company. On November 29, 2005, the Registrant's board of directors
approved an amendment to the Registrant's articles of incorporation to (i) increase the
number of authorized shares of capital stock to 910,000,000 shares, including 900,000,000
shares of common stock, par value $0.0001, and 10,000,000 shares of preferred stock, par
value $0.0001. On November 8, 2005, Park Avenue Group appointed Richard
Rubin to the board of directors of the
Registrant, which then appointed Mr. Rubin to be chief executive officer and chief
financial officer of the Registrant. New Business
Objectives of the Registrant As
a result of the bankruptcy proceeding, the Registrant has no present operations and has
determined to direct its efforts and limited resources to pursue potential new business
opportunities. The Registrant does not intend to limit itself to a particular industry and
has not established any particular criteria upon which it shall consider and proceed with
a business opportunity. There is currently only a limited trading market in the
Registrant's shares on the NASDAQ BB. There can be no assurance that there will be an
active trading market for our common stock. In the event that an active trading market
commences, there can be no assurance as to the market price of our shares of common stock,
whether any trading market will provide liquidity to investors, or whether any trading
market will be sustained. Registrant's
executive officer/director intends to devote such time as he deems necessary to carry out
the Registrant's affairs. The exact length of time required for the pursuit of any new
potential business opportunities is uncertain. No assurance can be made that the
Registrant will be successful in its efforts. We cannot project the amount of time that
our executive officer/director will actually devote to the Registrant's plan of operation. Plan of Operation We have no present operations or
revenues and our current activities are related to seeking new business opportunities,
including seeking an acquisition or merger with an operating company. If our management
seeks to acquire another business or pursue a new business opportunity, it would have
substantial flexibility in identifying and selecting a prospective business. Registrant
would not be obligated nor does management intend to seek pre-approval from our
shareholders. Under the laws of the State of Delaware, the consent of holders of a
majority of the issued and outstanding shares, acting without a shareholders meeting, can
approve an acquisition. The Registrant is entirely dependent on
the judgment of its executive officer/director in connection with pursuing a new business
opportunity or a selection process for a target operating company. In evaluating a
prospective new business opportunity or an operating company, he would consider, among
other factors, the following: (i) costs associated with effecting a transaction; (ii)
equity interest in and opportunity to control the prospective candidate; (iii) growth
potential of the target business; (iv) experience and skill of management and availability
of additional personnel; (v) necessary capital requirements; (vi) the prospective
candidate's competitive position; (vii) stage of development of the business opportunity;
(viii) the market acceptance of the business, its products or services; (ix) the
availability of audited financial statements of the potential business opportunity; and
(x) the regulatory environment that may be applicable to any prospective business
opportunity. The foregoing criteria are not intended
to be exhaustive and there may be other criteria that management may deem relevant. In
connection with an evaluation of a prospective or potential business opportunity,
management may be expected to conduct a due diligence review. Liquidity and Capital Resources We will use our limited personnel and
financial resources in connection with seeking new business opportunities, including
seeking an acquisition or merger with an operating company. It may be expected that
entering into a new business opportunity or business combination will involve the issuance
of a substantial number of restricted shares of common stock. If such additional
restricted shares of common stock are issued, our shareholders will experience a dilution
in their ownership interest in the Registrant. If a substantial number of restricted
shares are issued in connection with a business combination, a change in control may be
expected to occur. In
connection with our plan to seek new business opportunities and/or effecting a business
combination, we may determine to seek to raise funds from the sale of restricted stock or
debt securities.We have no agreements to issue any debt or equity securities and cannot
predict whether equity or debt financing will become available at terms acceptable to us,
if at all. There
are no limitations in our articles of incorporation on our ability to borrow funds or
raise funds through the issuance of restricted common stock to effect a business
combination. Our limited resources and lack of operating history may make it difficult to
do borrow funds or raise capital. Our inability to borrow funds or raise funds through the
issuance of restricted common stock required to effect or facilitate a business
combination may have a material adverse effect on our financial condition and future
prospects, including the ability to complete a business combination. To the extent that
debt financing ultimately proves to be available, any borrowing will subject us to various
risks traditionally associated with indebtedness, including the risks of interest rate
fluctuations and insufficiency of cash flow to pay principal and interest, including debt
of an acquired business. ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Back to Table of Contents We have not entered
into, and do not expect to enter into, financial instruments for trading or hedging
purposes. ITEM 4.
CONTROLS AND PROCEDURES Back
to Table of Contents Evaluation of Disclosure Controls and Procedures Our Chief Executive Officer/Chief Financial Officer evaluated the effectiveness of the
design and operation of our disclosure controls and procedures (as such term is defined in
Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act").
Disclosure controls and procedures are the controls and other procedures that we designed
to ensure that we record, process, summarize and report in a timely manner the information
we must disclose in reports that we file with or submit to the Securities and Exchange
Commission under the Exchange Act. Based on this evaluation, we have concluded that our
disclosure controls and procedures were effective as of the end of the period covered by
this report. Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting or in other
factors identified in connection with the evaluation required by paragraph (d) of Exchange
Act Rules 13a-15 or 15d-15 that occurred during the quarter ended September 30, 2008 that
have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting. PART II - OTHER INFORMATION ITEM 1. LEGAL
PROCEEDINGS Back to Table of
Contents None. ITEM 1A.
RISK FACTORS Back to Table of
Contents In addition to the other
information set forth in this report, you should carefully consider the factors discussed
in Part I, Item 1. Description of Business, subheading Risk Factors in
our Annual Report on Form 10-KSB for the year ended December 31, 2007, which
could materially affect our business, financial condition or future results. The risks
described in our Annual Report on Form 10-KSB are not the only risks facing our
company. Additional risks and uncertainties not currently known to us or that we currently
deem to be immaterial also may materially adversely affect our business, financial
condition and/or operating results. ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Back to Table of Contents None. ITEM
3. DEFAULTS UPON SENIOR SECURITIES Back to Table of Contents None. ITEM
4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS Back to Table of Contents None. ITEM
5. OTHER INFORMATION Back
to Table of Contents None. ITEM
6. EXHIBITS Back to Table of
Contents (a) The following documents are filed as exhibits to
this report on Form 10-QSB or incorporated by reference herein. Any document incorporated
by reference is identified by a parenthetical reference to the SEC filing that included
such document. Exhibit
No. (b) Reports on Form 8-K during the quarter covered by this report:
None. SIGNATURES Pursuant to the
requirements of the Securities Exchange Act of 1934, this report has been signed below by
the following persons on behalf of the registrant and in the capacities and on the date
indicated. /s/ Richard
Rubin Financial
Statements for the three-and nine month periods ended September 30, 2008 and 2007 American Biogenetic Sciences, Inc. Assets Liabilities
and Stockholders' Deficiency American Biogenetic Sciences, Inc. AMERICAN BIOGENETIC SCIENCES, INC. 1. Basis of Presentation American Biogenetic Sciences, Inc. (the "Company",
We or "ABS") was incorporated in Delaware on September 1, 1983.
Prior to filing for bankruptcy under chapter 7, the Company engaged in the research,
development and production of bio-pharmaceutical products. The Financial Statements presented herein have been prepared by us in
accordance with the accounting policies described in our December 31, 2007 Annual Report
on Form 10-KSB and should be read in conjunction with the Notes to Consolidated Financial
Statements which appear in that report. The preparation of these financial statements in conformity with
accounting principles generally accepted in the United States requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses, and related disclosure of contingent assets and liabilities. On an on going
basis, we evaluate our estimates, including those related intangible assets, income taxes,
insurance obligations and contingencies and litigation. We base our estimates on
historical experience and on various other assumptions that are believed to be reasonable
under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities that are not readily apparent from other
resources. Actual results may differ from these estimates under different assumptions or
conditions. In the opinion of management, the information furnished in this Form
10-Q reflects all adjustments necessary for a fair statement of the financial position and
results of operations and cash flows as of and for the three- and nine month periods ended
September 30, 2008 and 2007. All such adjustments are of a normal recurring nature. The
Financial Statements have been prepared in accordance with the instructions to Form 10-Q
and therefore do not include some information and notes necessary to conform with annual
reporting requirements Fresh Start Accounting: On September 19, 2002 all of
the Companys assets were transferred to the chapter 7 trustee in settlement of all
outstanding corporate obligations. We adopted "fresh-start" accounting as of
September 20, 2002 in accordance with procedures specified by AICPA Statement of Position
("SOP") No. 90-7, "Financial Reporting by Entities in Reorganization under
the Bankruptcy Code." All results for periods subsequent to September 19, 2002 are referred
to as those of the "Successor Company". The results of operations and cash flows
as presented on the 2002 financial statements reflect the predecessor company. The
successor company had no transactions between September 19 and the end of the reporting
period, December 31, 2002. In accordance with SOP No. 90-7, the reorganized value of the Company
was allocated to the Company's assets based on procedures specified by SFAS No. 141,
"Business Combinations". Each liability existing at the plan sale date, other
than deferred taxes, was stated at the present value of the amounts to be paid at
appropriate market rates. It was determined that the Company's reorganization value
computed immediately before September 20, 2002 was $0. We adopted "fresh-start"
accounting because holders of existing voting shares immediately before filing and
confirmation of the sale received less than 50% of the voting shares of the emerging
entity and its reorganization value is less than its post-petition liabilities and allowed
claims. The accounts of the former subsidiaries were not included in the sale
and have not been carried forward. 2. Bankruptcy Proceedings On September 19, 2002, the Registrant filed a voluntary Chapter 7
petition under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of
New York (case no. 02-86689). On November 4, 2005, the Bankruptcy Court approved an Order
confirming the sale of debtor's interest in personal property to Park Avenue Group Inc.
The material terms of the transaction confirmed by Bankruptcy Court authorized Park Avenue
Group to appoint new members to the Registrant's board of directors and authorized the
newly-appointed board of directors to amend the Article of Incorporation with respect to
the capital stock of the Company. The accounts of the former subsidiaries were not included in the sale
and have not been carried forward. Resultant Change in Control: In connection with the Order
confirming the sale of debtor's interest in certain intangible personal property to Park
Avenue Group Inc. approved by the U.S. Bankruptcy Court Eastern District of New York on
November 4, 2005, the Court authorized a change in control pursuant to which Richard Rubin
became our sole director on November 29, 2005, and was appointed CEO by the new board of
directors on November 29, 2005. The Court order further provided that the sale was free
and clear of liens, claims and interests of others and that the sale was free and clear of
any and all other real or personal property interests, including any interests in
ABSs subsidiaries. 3. Earnings/Loss Per Share Basic earnings per share is computed by dividing income available to
common shareholders (the numerator) by the weighted-average number of common shares
outstanding (the denominator) for the period. Diluted earnings per share assume that any
dilutive convertible securities outstanding were converted, with related preferred stock
dividend requirements and outstanding common shares adjusted accordingly. It also assumes
that outstanding common shares were increased by shares issuable upon exercise of those
stock options for which market price exceeds the exercise price, less shares which could
have been purchased by us with the related proceeds. In periods of losses, diluted loss
per share is computed on the same basis as basic loss per share as the inclusion of any
other potential shares outstanding would be anti-dilutive. 4. Related Party Transactions not Disclosed Elsewhere: Due related parties and Fair value of services: The principal
stockholder provided, without cost to the Company, his services and office space. The
total of these expenses was $27,000 and $9,000 for nine month and three month period ended
September 30, 2008, respectively, and was $12,000 and $0 for nine month and three month
period ended September 30, 2007, respectively. These expenses were reflected in the
statement of operations as general and administrative expenses. 5. New Accounting Standards In December 2007, the FASB issued SFAS No. 141(R), Business
Combinations. This Statement replaces SFAS No. 141, Business Combinations. This
Statement retains the fundamental requirements in Statement 141 that the acquisition
method of accounting (which Statement 141 called the purchase method) be used for all
business combinations and for an acquirer to be identified for each business combination.
This Statement also establishes principles and requirements for how the acquirer: a)
recognizes and measures in its financial statements the identifiable assets acquired, the
liabilities assumed, and any noncontrolling interest in the acquiree; b) recognizes and
measures the goodwill acquired in the business combination or a gain from a bargain
purchase and c) determines what information to disclose to enable users of the financial
statements to evaluate the nature and financial effects of the business combination. SFAS
No. 141(R) will apply prospectively to business combinations for which the acquisition
date is on or after Companys fiscal year beginning October 1, 2009. While the
Company has not yet evaluated this statement for the impact, if any, that SFAS No. 141(R)
will have on its consolidated financial statements, the Company will be required to
expense costs related to any acquisitions after September 30, 2009. In May 2008, the FASB issued SFAS No. 162, The Hierarchy of
Generally Accepted Accounting Principles. SFAS 162 identifies the sources of
accounting principles and the framework for selecting the principles used in the
preparation of financial statements of nongovernmental entities that are presented in
conformity with generally accepted accounting principles (GAAP) in the United States. SFAS
162 is effective 60 days following the SECs approval of the Public Company
Accounting Oversight Board amendments to AU Section 411, The Meaning of Present Fairly
in Conformity With Generally Accepted Accounting Principles. Our Company is currently
evaluating the impact of SFAS 162 on its financial statements but does not expect it to
have a material effect. Accounting Principles. Our Management is currently evaluating the
impact of SFAS 162 on the Company's financial statements but does not expect it to have a
material effect.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 10-Q
________________________________
(Exact Name Of Registrant
As Specified In Its Charter)
Delaware
11-2655906
(State of Incorporation)
(I.R.S. Employer
Identification No.)
90
John Street, Suite 626, New York, NY
10038
(Address of Principal
Executive Offices)
(ZIP Code)
Large accelerated
filer ¨
Accelerated filer ¨
Non-Accelerated
filer ¨
Smaller reporting
company x
Item
Description
Page
3
3
ITEM 3.
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
6
6
6
ITEM 1A.
RISK FACTORS
6
6
6
6
6
ITEM 6.
EXHIBITS
6
Description
31
Certification of CEO/CFO
pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
32
Certification of CEO/CFO
pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
Richard Rubin
CEO, CFO and Chairman
Dated: November 14, 2008
September
30, 2008
December
31, 2007
(Unaudited)
Current assets:
Cash
$
18
$
23
Prepaid expenses
0
0
Total current assets
18
23
Total assets
$
18
$
23
Current liabilities:
Accounts payable -
trade
$
500
$
0
Advances from and
accruals due to related parties
40,456
13,186
Total current liabilities
40,956
13,186
Stockholders' deficiency:
Common stock, 900,000,000
shares authorized, $0.0001 par value;
217,749,909
shares issued and outstanding at September 30, 2008; and
216,749,909
shares issued and outstanding at December 31, 2007
21,775
21,675
Additional paid-in
capital
24,525
24,125
Subscription
receivable
0
(2,270)
Accumulated
deficit
(87,238)
(56,693)
Total
stockholders' deficiency
(40,938)
(13,163)
Total liabilities and stockholders' deficiency
$
18
$
23
See
notes to unaudited interim financial statements.
American
Biogenetic Sciences, Inc.
Statement of Operations
Three Months
Three Months
Nine Months
Nine Months
Ended
Ended
Ended
Ended
September 30, 2008
September 30, 2007
September 30, 2008
September 30, 2007
(Unaudited)
(Unaudited)
(Unaudited)
(Unaudited)
Revenue
$
0
$
0
$
0
$
0
Costs and expenses:
General and administrative
9,527
500
30,545
13,726
Interest
0
0
0
0
Total costs and expenses
9,527
500
30,545
13,726
Net loss
$
(9,527)
$
(500)
$
(30,545)
$
(13,726)
Basic and diluted per shares amounts:
Basic and diluted net loss
$
(0.00)
$
(0.00)
$
(0.00)
$
(0.00)
Weighted average shares outstanding:
Basic and diluted
217,749,909
184,949,909
217,640,420
184,949,909
See notes to unaudited interim
financial statements.
Nine Months
Nine Months
Ended
Ended
September 30, 2008
September 30, 2007
(Unaudited)
(Unaudited)
Cash flows from operating activities:
Net loss
$
(30,545)
(13,276)
Adjustment required to reconcile net loss to
cash used in operating activities:
Fair value of expenses provided
from related parties
27,000
12,000
Expenses paid by related parties
2,500
500
Increase (decrease) in accounts
payable and accrued expenses
500
0
Cash
flows used by operating activities
$
(545)
(776)
Cash flows from investing
activities:
Cash
used in investing activities
0
0
Cash flows from financing activities:
Proceeds from the issuance of
common stock
500
3,780
Proceeds from related party
borrowings
40
0
Cash
provided by financing activities
540
3,780
Change in cash
(5)
3,004
Cash - beginning of period
23
19
Cash - end of period
$
18
$
3,023
See notes to
unaudited interim financial statements.
Notes to Unaudited Interim Financial Statements
September 30, 2008
I, Richard Rubin, certify that:
1. I have reviewed this quarterly report of American Biogenetic Sciences, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as 4efined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and
5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether r not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.
Date: November 14, 2008
/s/ Richard Rubin
CEO, CFO and Chairman
Statement Pursuant to Section 906 of Sarbanes-Oxley Act of 2002
The undersigned, Richard Rubin, CEO, CFO and Chairman of American Biogenetic Sciences, Inc, a Delaware corporation, hereby makes the following certification as required by Section 906(a) of the Sarbanes-Oxley Act of 2002, with respect to the following of this report filed pursuant to Section 15(d) of the Securities Exchange Act of 1934: Quarterly Report on Form 10-Q for the period ended September 30, 2008.
The undersigned certifies that the above quarterly report fully complies with the requirements of Section 15(d) of the Securities Exchange Act of 1934, and information contained in the above report fairly presents, in all respects, the financial condition of American Biogenetic Sciences, Inc. and results of its operations.
Date: November 14, 2008
/s/ Richard Rubin
CEO, CFO and Chairman